

## Myomo, Inc. Issues November 2017 Shareholder Letter

*Provides an Update on Third Quarter 2017 and Ongoing Commercial Activities*

CAMBRIDGE, Mass., November 7, 2017 – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today issued a letter to shareholders to give an update on third quarter 2017 and ongoing MyoPro® commercial activities.

An accompanying digital shareholder letter can be viewed at: [shareholderletters.myomo.com/q3-17](http://shareholderletters.myomo.com/q3-17).


Dear Fellow Shareholders:

Welcome to the first edition of our Investor Relations digital shareholder letter, whose purpose is to keep you informed about Myomo's progress. Since completing our IPO in June, we have been implementing various sales and marketing programs to grow the company. We established additional MyoPro Centers of Excellence to distribute our products to patients around the country; increased our Marketing presence online and begun our international expansion. We are leveraging our FDA registered, CE Marked, and only commercial, proprietary technology to restore function to the millions of patients with upper limb paralysis. .

We believe we have the strategic focus, business model, and an expanding operational footprint to ably serve this market, facilitating our growth.

Thank you for your investment in MYO shares, which provides us the resources to grow the business and create shareholder value over time.

Sincerely;



Paul R. Gudonis  
Chairman & Chief Executive Officer

### **About Myomo**

Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many



are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit [www.myomo.com](http://www.myomo.com).

### **Forward Looking Statements**

This press release contains forward-looking statements regarding the Company's future business expectations, including the launch of MyoPro for Veterans, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo's financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

### **For Myomo:**

[ir@myomo.com](mailto:ir@myomo.com)

### **Investor Relations:**

Vivian Cervantes

PCG Advisory

212-554-5482

[vivian@pcgadvisory.com](mailto:vivian@pcgadvisory.com)

### **Public Relations:**

Rachel Robbins

Greenough

617-275-6521

[rrobbins@greenough.biz](mailto:rrobbins@greenough.biz)